A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Varlilumab Patients With Advanced Melanoma

Trial Profile

A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Varlilumab Patients With Advanced Melanoma

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Glembatumumab vedotin (Primary) ; Varlilumab (Primary) ; Nivolumab; Pembrolizumab
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Celldex Therapeutics Inc
  • Most Recent Events

    • 16 Apr 2018 According to a Celldex Therapeutics media release, status changed from not yet recruiting to discontinued, because based on the data from METRIC study, company has decided to discontinue the glembatumumab vedotin program across all indications.
    • 07 Mar 2018 According to a Celldex Therapeutics media release, enrollment in the glembatumumab vedotin plus checkpoint inhibitor cohort has been completed.
    • 13 Dec 2017 Planned number of patients changed from 120 to 130.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top